Emeramide (BDTH2) (Synonyms: BDTH2, NBMI) |
|
カタログ番号GC31671
|
Emeramide (BDTH2)は脂質溶解性の重金属キレート剤と抗酸化剤である。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 351994-94-0
Sample solution is provided at 25 µL, 10mM.
Emeramide (BDTH2)は脂質溶解性の重金属キレート剤と抗酸化剤である[1]。Emeramideは「軟金属」(例えば水銀(Hg2+)、鉛(Pb2+)とカドミウム(Cd2+))と共に強い共有結合または半共有結合チオ硫化物錯体を形成し、よってこれらの金属の遊離濃度と毒性を減らす[2]。Emeramideはグルタチオン(GSH)などの細胞内チオール/抗酸化システムの回復または保護を助け、よって金属誘発の酸化ストレスを軽減する[3]。Emeramideは主に、重金属中毒に対する潜在的な治療薬である[4]。
U-87 MG細胞で、高濃度のEmeramide (0-200µM;24時間)は細胞の生存率を減らす[5]。HepG2細胞で、Emeramide (0-100µM;24時間)の事前処理は、CuSO4誘発の細胞死を減らし、ROSのレベルを減らした[6]。
H67Dノックイン変異マウスで、Emeramide (450mg/kg;経口投与;6週間)の経口投与は、脳と肝臓で鉄の蓄積を減らす[7]。
References:
[1]. Secor J D, Kotha S R, Gurney T O, et al. Novel lipid-soluble thiol-redox antioxidant and heavy metal chelator, N, N′-bis (2-mercaptoethyl) isophthalamide (NBMI) and phospholipase D-specific inhibitor, 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) attenuate mercury-induced lipid signaling leading to protection against cytotoxicity in aortic endothelial cells[J]. International journal of toxicology, 2011, 30(6): 619-638.
[2]. Wang Y, Zhang S, Bian J, et al. A method for the rapid detection of heavy metal mercury ions based on a novel mercury chelator N, N'-bis (2-mercaptoethyl) isophthalamide[J]. Food Chemistry, 2025, 468: 142486.
[3]. Secor J D, Kotha S R, Gurney T O, et al. Novel lipid-soluble thiol-redox antioxidant and heavy metal chelator, N, N′-bis (2-mercaptoethyl) isophthalamide (NBMI) and phospholipase D-specific inhibitor, 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) attenuate mercury-induced lipid signaling leading to protection against cytotoxicity in aortic endothelial cells[J]. International journal of toxicology, 2011, 30(6): 619-638.
[4]. Geier D A, Geier M R. Reductions in plasma and urine mercury concentrations following N, N′ bis-(2-mercaptoethyl) isophthalamide (NBMI) therapy: a post hoc analysis of data from a randomized human clinical trial[J]. Biometals, 2024, 37(2): 433-445.
[5]. Gadde R, Betharia S. N, N′ bis-(2-mercaptoethyl) isophthalamide (NBMI) exerts neuroprotection against lead-induced toxicity in U-87 MG cells[J]. Archives of Toxicology, 2021, 95(8): 2643-2657.
[6]. Gadde R, Betharia S. NBMI Exerts Protection Against Copper Overload in HepG2 and SH‐SY5Y Cell Lines[J]. The FASEB Journal, 2022, 36.
[7]. Cheng R, Gadde R, Fan Y, et al. Reversal of genetic brain iron accumulation by N, N′-bis (2-mercaptoethyl) isophthalamide, a lipophilic metal chelator, in mice[J]. Archives of Toxicology, 2022, 96(7): 1951-1962.
| 細胞実験[1]: | |
細胞株 | U-87 MG細胞 |
準備方法 | 2 × 104個の細胞/ウェルの密度で、細胞を透明底の不透明96ウェルのプレートに播種した。一晩中接着の後、PbAc (0-300µM) で24または48時間、Emeramide (0-200µM)で24時間、またはDMSA (0-500µM)で24時間処理し、個別の毒性プロファイルを作成した。 |
反応条件 | 0-200µM;24時間 |
アプリケーション | 高濃度のEmeramideは、細胞の生存率を減らす。 |
| 動物実験 [2]: | |
動物モデル | H67Dノックイン変異マウス |
準備方法 | H67Dノックイン変異マウスと対照の野生型(WT)マウス(5-6週齢、n=6-8/グループ)を、12時間の昼夜循環の環境で飼育し、飼料と水を自由に摂取させた。マウスにはEmeramide (体重1kgあたり450mg)、Deferiprone (100mg/kg)または溶媒(0.5%のCarboxymethylcellulose )を6週間、毎日経口投与した。 |
投与形態 | 450mg/kg;経口投与;6週間 |
アプリケーション | Emeramideの経口投与は、脳と肝臓における鉄の蓄積を減らす。 |
References: | |
| Cas No. | 351994-94-0 | SDF | |
| 同義語 | BDTH2, NBMI | ||
| Canonical SMILES | O=C(C1=CC=CC(C(NCCS)=O)=C1)NCCS | ||
| Formula | C12H16N2O2S2 | M.Wt | 284.4 |
| 溶解度 | DMSO : 100 mg/mL (351.62 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C,unstable in solution, ready to use. |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5162 mL | 17.5809 mL | 35.1617 mL |
| 5 mM | 703.2 μL | 3.5162 mL | 7.0323 mL |
| 10 mM | 351.6 μL | 1.7581 mL | 3.5162 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)















